Biotechnology company Kyverna Therapeutics Inc (KYTX) recently announced that its chimeric antigen receptor T cell therapy Miv-Cel (KYV-101) for stiff person syndrome (SPS) has completed the primary analysis in the clinical trial named KYSA-8.

老虎证券2026/04/21 23:12

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

A bitcoin address dormant for 16.2 years has been activated, containing 50 BTC

AiCoin•2026/11/13 04:23

Updated version 2-Keurig Dr Pepper raises 2 billions USD through stock offering, aiming to reduce debt before the spin-off.

路透社•2026/11/13 04:16

Yen breaches the 160 level again! Japanese finance minister vows to "join forces" with the US Treasury to address unilateral volatility

After the yen fell below the critical 160 level, the Japanese finance minister stated that Japan would closely cooperate with the US Treasury Department to address unilateral volatility, reigniting speculation of joint intervention.

智通财经•2026/11/13 03:46

BUZZ - Australia's IDP Education set for weekly gain on revised Blackstone acquisition offer

路透社•2026/11/13 03:01